10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
BACKGROUND: During the United Kingdom Prospective Diabetes Study (UKPDS), patients with type 2 diabetes mellitus who received intensive glucose therapy had a lower risk of microvascular complications than did those receiving conventional dietary therapy. We conducted post-trial monitoring to determine whether this improved glucose control persisted and whether such therapy had a long-term effect on macrovascular outcomes. METHODS: Of 5102 patients with newly diagnosed type 2 diabetes, 4209 were randomly assigned to receive either conventional therapy (dietary restriction) or intensive therapy (either sulfonylurea or insulin or, in overweight patients, metformin) for glucose control. In post-trial monitoring, 3277 patients were asked to attend annual UKPDS clinics for 5 years, but no attempts were made to maintain their previously assigned therapies. Annual questionnaires were used to follow patients who were unable to attend the clinics, and all patients in years 6 to 10 were assessed through questionnaires. We examined seven prespecified aggregate clinical outcomes from the UKPDS on an intention-to-treat basis, according to previous randomization categories. RESULTS: Between-group differences in glycated hemoglobin levels were lost after the first year. In the sulfonylurea-insulin group, relative reductions in risk persisted at 10 years for any diabetes-related end point (9%, P=0.04) and microvascular disease (24%, P=0.001), and risk reductions for myocardial infarction (15%, P=0.01) and death from any cause (13%, P=0.007) emerged over time, as more events occurred. In the metformin group, significant risk reductions persisted for any diabetes-related end point (21%, P=0.01), myocardial infarction (33%, P=0.005), and death from any cause (27%, P=0.002). CONCLUSIONS: Despite an early loss of glycemic differences, a continued reduction in microvascular risk and emergent risk reductions for myocardial infarction and death from any cause were observed during 10 years of post-trial follow-up. A continued benefit after metformin therapy was evident among overweight patients. (UKPDS 80; Current Controlled Trials number, ISRCTN75451837.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The potential risks of intensive glycemic control may be obviated by incorporating agents that are not associated with hypoglycemia, especially in persons with frequent severe hypoglycemia, hypoglycemia unawareness, or a very long duration of DM, and particularly in the presence of established and advanced atherosclerosis, advanced age, and terminal illness.69,70,76–81”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [79]
In the citing paper
“it is worth noting the legacy effects of significant, early glucose lowering on macrovascular and microvascular complications observed in the UKPDS study [3,37].”
In the citing paper
“Although recidivism in glycemia is typically observed across all interventions in diabetes [4,5,6,29] including pharmaceutical interventions [3,37]”
In the citing paper
“Numerous studies have demonstrated the clinical benefits of early achievement of nearnormal glycemic control in individuals with type 1 diabetes and type 2 diabetes (77-83).”
From Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range (2019) · cites this paper as [81]
In the citing paper
“since optimal glycaemic control reduces the risk of both microvascular and macrovascular complications (36, 55).”
From Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus (2024) · cites this paper as [55]
31 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationEuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Turner, R. C., Millns, H., Neil, H. A. W., Stratton, I. M., Manley, S. E., Matthews, D. R., & Holman, R. R. (1998) · BMJ · doi:10.1136/bmj.316.7134.823 · Cited by 2,014
Self-citationAntithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Interval estimation for the difference between independent proportions: comparison of eleven methods
Newcombe, R. G. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980430)17:8<873::aid-sim779>3.0.co;2-i · Cited by 1,851
(2000) · New England Journal of Medicine · doi:10.1056/nejm200002103420603 · Cited by 1,534
The Role of Advanced Glycation End Products in Progression and Complications of Diabetes
Goh, S.-Y., & Cooper, M. E. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1817 · Cited by 987
Detection of Deep-Vein Thrombosis by Real-Time B-Mode Ultrasonography
Lensing, A. W. A., Prandoni, P., Brandjes, D., Huisman, P. M., Vigo, M., Tomasella, G., Krekt, J., ten Cate, J. W., Huisman, M. V., & Büller, H. R. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902093200602 · Cited by 875 · cited 1×
“Follow-up. Patients with normal findings at the initial diagnostic workup were scheduled for an end of follow-up visit after 3 months, which consisted of (1) a standardized interview to assess their general health status, chest or leg complaints, and history of hospital admission for any cause; ( 2 ) a physical examin…”
BackgroundIntensive Diabetes Therapy and Carotid Intima–Media Thickness in Type 1 Diabetes Mellitus
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa022314 · Cited by 815
Long-term follow-up after tight control of blood pressure in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Neil, H. A. W., & Matthews, D. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806359 · Cited by 762
Self-citationNEED FOR LONG-TERM ANTICOAGULANT TREATMENT IN SYMPTOMATIC CALF-VEIN THROMBOSIS
LAGERSTEDT, C. (1985) · The Lancet · doi:10.1016/s0140-6736(85)90459-3 · Cited by 569 · cited 2×
“AR symptom duration, mean (SD), mo 6.6 (3.4) 6.9 (3.5) .22 6.7 (3.8) 5.8 (3.1) .001 5.9 (3.2) Duration of disease, mean (SD), y 11.9 (9.3) 12.1 (9.4) .66 12.0 (9.4) 13.1 (9.8) .002 12.8 (9.7) Concomitant asthma, No. (%) 126 (26) 122 (25) .71 248 ( 25 ) 1,310 (31) .001 1,558 (29.7) Previous cortisone treatment, No. (%)…”
InfluentialUK prospective diabetes study (UKPDS): VIII. Study design, progress and performance
UK Prospective Diabetes Study Group (1991) · Diabetologia · doi:10.1007/bf00400195 · Cited by 543
Stettler, C., Allemann, S., Jüni, P., Cull, C. A., Holman, R. R., Egger, M., Krähenbühl, S., & Diem, P. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.09.015 · Cited by 467
Self-citationCogo, A., Lensing, A. W. A., Koopman, M. M. W., Piovella, F., Siragusa, S., Wells, P. S., Villalta, S., Büller, H. R., Turpie, A. G. G., & Prandoni, P. (1998) · BMJ · doi:10.1136/bmj.316.7124.17 · Cited by 406
Cogo, A. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.153.24.2777 · Cited by 327
Bernardi, E., Prandoni, P., Lensing, A. W. A., Agnelli, G., Guazzaloca, G., Scannapieco, G., Piovella, F., Verlato, F., Tomasi, C., Moia, M., et al. (1998) · BMJ · doi:10.1136/bmj.317.7165.1037 · Cited by 230
Wells, P. S., Brill-Edwards, P., Stevens, P., Panju, A., Patel, A., Douketis, J., Massicotte, M. P., Hirsh, J., Weitz, J. I., Kearon, C., et al. (1995) · Circulation · doi:10.1161/01.cir.91.8.2184 · Cited by 226
Schwarz, T., Halbritter, K., Beyer, J., Siegert, G., Oettler, W., Schmidt, B., Schroeder, H., & Schellong, S. (2003) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613436 · Cited by 217
Ultrasonography and Diagnosis of Venous Thromboembolism
Zierler, B. K. (2004) · Circulation · doi:10.1161/01.cir.0000122870.22669.4a · Cited by 213
Kearon, C., Ginsberg, J. S., Douketis, J., Crowther, M., Brill-Edwards, P., Weitz, J. I., & Hirsh, J. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-2-200107170-00011 · Cited by 197
Simplification of the Diagnostic Management of Suspected Deep Vein Thrombosis
Kraaijenhagen, R. A., Piovella, F., Bernardi, E., Verlato, F., Beckers, E. A. M., Koopman, M. M. W., Barone, M., Camporese, G., Potter van Loon, B. J., Prins, M. H., et al. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.8.907 · Cited by 192
Clinical relevance of distal deep vein thrombosis. Review of literature data.
Righini, M., Paris, S., Gal, G. L., Laroche, J.-P., Perrier, A., & Bounameaux, H. (2006) · PubMed · Cited by 169
Mallard, L., Elias, M., Alquier, C., Guidolin, F., Gauthier, B., Viard, A., Mahouin, P., Vinel, A., Boccalon, H., & Élias, A. (2003) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613435 · Cited by 145
Stevens, S. M., Elliott, C. G., Chan, K. J., Egger, M. J., & Ahmed, K. M. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-12-200406150-00007 · Cited by 142
Thrombosis in the Emergency Department
Anderson, D. R., Wells, P. S., Stiell, I. G., MacLeod, B. A., Simms, M. H., Gray, L. C., Robinson, K. S., Bormanis, J., Mitchell, M. J., Lewandowski, B. J., et al. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.5.477 · Cited by 105
Tick, L. W., Ton, E., van Voorthuizen, T., Hovens, M. M. C., Leeuwenburgh, I., Lobatto, S., Stijnen, P. J., van der Heul, C., Huisman, P. M., Kramer, M. H. H., et al. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01347-5 · Cited by 98
Lewis, B. D., James, E. M., Welch, T. L., Joyce, J. W., Hallett, J. W., & Weaver, A. L. (1994) · Radiology · doi:10.1148/radiology.192.3.8058929 · Cited by 90
Gaitini, D. E. (2006) · Journal of Clinical Ultrasound · doi:10.1002/jcu.20236 · Cited by 87 · cited 1×
“... (SD), y 11.9 (9.3) 12.1 (9.4) .66 12.0 (9.4) 13.1 (9.8) .002 12.8 (9.7) Concomitant asthma, No. (%) 126 (26) 122 (25) .71 248 (25) 1,310 (31) .001 1,558 (29.7) Previous cortisone treatment, No. (%) 250 (51) 212 (43) .009 462 (47) 1,894 (45) .16 2,356 (45.0) Previous histamine blocker treatment, No. (%) 432 (89) 43…”
InfluentialUK Prospective Diabetes Study Group (1994) · Diabetic Medicine · doi:10.1111/j.1464-5491.1994.tb02032.x · Cited by 85
Kearon, C., Ginsberg, J. S., Douketis, J. D., Crowther, M. A., Turpie, A. G. G., Bates, S. M., Lee, A. Y. Y., Brill-Edwards, P. A., Finch, T., & Gent, M. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-7-200504050-00007 · Cited by 61
Colour flow imaging of calf vein thrombosis
Baxter, G. M., Duffy, P. E., & Partridge, E. (1992) · Clinical Radiology · doi:10.1016/s0009-9260(05)80445-3 · Cited by 55
The UKPDS and its global impact
GENUTH, S. M. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02504.x · Cited by 44
Ultrasound in the detection of venous thromboembolism
Blaivas, M. (2007) · Critical Care Medicine · doi:10.1097/01.ccm.0000260672.13913.fd · Cited by 42
Impact of the UKPDS—an overview
Home, P. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02501.x · Cited by 41
Predictive Value of Compression Ultrasonography for Deep Vein Thrombosis in Symptomatic Outpatients
Birdwell, B. G., Raskob, G. E., Whitsett, T. L., Durica, S. S., Comp, P. C., George, J. N., Tytle, T. L., Owen, W. L., & McKee, P. A. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.3.309 · Cited by 36
Diagnostic strategies for the management of patients with clinically suspected deep-vein thrombosis
Kraaijenhagen, R. A., Lensing, A. W. A., Lijmer, J. G., Prandoni, P., Prins, M. H., Ginsberg, J. S., & Buller, H. R. (1997) · Current Opinion in Pulmonary Medicine · doi:10.1097/00063198-199707000-00006 · Cited by 35 · cited 1×
“AR symptom duration, mean (SD), mo 6.6 (3.4) 6.9 (3.5) .22 6.7 (3.8) 5.8 (3.1) .001 5.9 (3.2) Duration of disease, mean (SD), y 11.9 (9.3) 12.1 (9.4) .66 12.0 (9.4) 13.1 (9.8) .002 12.8 (9.7) Concomitant asthma, No. (%) 126 (26) 122 (25) .71 248 (25) 1,310 ( 31 ) .001 1,558 (29.7) Previous cortisone treatment, No. (%)…”
InfluentialDiagnosis of Deep Venous Thrombosis by Duplex Sonography
Mantoni, M. Y. (1989) · Acta Radiologica · doi:10.1177/028418518903000602 · Cited by 27 · cited 1×
“Follow-up. Patients with normal findings at the initial diagnostic workup were scheduled for an end of follow-up visit after 3 months, which consisted of ( 1 ) a standardized interview to assess their general health status, chest or leg complaints, and history of hospital admission for any cause; (2) a physical examin…”
BackgroundImberti, D., Ageno, W., Dentali, F., Giorgi‐Pierfranceschi, M., Croci, E., & Garcia, D. A. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01940.x · Cited by 25
McIlrath, S. T., Blaivas, M., & Lyon, M. L. (2006) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2005.11.020 · Cited by 25
One-Time Comprehensive Ultrasonography To Diagnose Deep Venous Thrombosis: Is That the Solution?
Kheir, D. E., & Buller, H. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-12-200406150-00016 · Cited by 18
Hull, R. D. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-7-200504050-00015 · Cited by 17
Bounameaux, H., Righini, M., & Perrier, A. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.01030.x · Cited by 13
Righini, M., Bounameaux, H., & Gal, G. L. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-11-200412070-00017 · Cited by 4
Research works printed but not linked: 3
- 1959, Stat Bull Metrop Insur Co, 40, 1
- Nathan DM, 2005, N Engl J Med, 22, 2643
- 1993, N Engl J Med, 329, 997
Cited by
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Oxidative stress and diabetic complications
Giacco, F., & Brownlee, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.223545 · Cited by 5,461
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Metadata
- Authors
- Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W.
- Affiliations
- Churchill Hospital (GB)
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- NIHR Oxford Biomedical Research Centre (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-10-09
- Volume
- 359
- Issue
- 15
- Pages
- 1577-1589
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2171294019
- Semantic Scholar
- 796f87021518c0bff851ff1ade5f780e3569e4ae
- Cited by
- 7,751
- References
- 55
- Citations by year
- 2026: 194 · 2025: 243 · 2024: 322 · 2023: 387 · 2022: 430 · 2021: 441 · 2020: 451 · 2019: 420 · 2018: 442 · 2017: 480 · 2016: 535 · 2015: 511 · 2014: 529 · 2013: 474 · 2012: 482
- FWCI
- 337.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- National Institute for Health and Care Research
- British Heart Foundation
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, tight glycemic control, glycemic control, metformin, sulfonylureas, insulin therapy, dietary therapy, microvascular complications, macrovascular outcomes, myocardial infarction, mortality, HbA1c, post-trial follow-up, UKPDS
- MeSH terms
- Aged, Blood Glucose, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Myocardial Infarction, Risk, Sulfonylurea Compounds, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.